2,5-Diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics

Journal of Medicinal Chemistry

Volumn 48, Issue 22, 2005, Pages 6956-6969

  Borthwick, Alan D ^a   Davies, Dave E ^a   Exall, Anne M ^a   Livermore, David G ^a   Sollis, Steve L ^a   Nerozzi, Fabrizio ^a   Allen, Michael J ^b   Perren, Marion ^b   Shabbir, Shalia S ^a   Woollard, Patrick M ^a   Wyatt, Paul G ^c  

^a Cell Biology Unit   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2',4' DIFLUOROPHENYLDIKETOPIPERAZINE DERIVATIVE; 2,5 DIKETOPIPERAZINE DERIVATIVE; ATOSIBAN; OXYTOCIN ANTAGONIST; OXYTOCIN RECEPTOR; UNCLASSIFIED DRUG; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ARTICLE; CHIRALITY; DOG; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CONFORMATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IN VIVO STUDY; NONHUMAN; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CRYSTALLOGRAPHY, X-RAY; DOGS; HUMANS; MOLECULAR STRUCTURE; PIPERAZINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; SERUM ALBUMIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; UTERINE CONTRACTION; VASOTOCIN;

EID: 27444444293     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050557v     Document Type: Article

References (31)

1. Goldenberg, R. L.; Rouse, D. Prevention of premature birth. N. Engl J. Med. 1998, 339, 313.
2. (a) Gyetvai, V.; Hannah, M. E.; Hodnett, E. D.; Ohlsson, A. Tocolytics for preterm labor: A systematic review. Obstet. Gynecol 1999, 94, 869-877.
3. (b) Enkin, M.; Kierse, M.; Neilson, J.; et al. Preterm Labour: A Guide to Effective Care in Pregnancy and Childbirth, 3rd ed.; Oxford University Press: Oxford, U.K., 2000; pp 211-225.
4. (c) Coomarasamy, A.; Knox, E. M.; Gee, H.; Khan, K. S. Oxytocin antagonists for tocolysis in preterm labour. A systematic review. Med. Sci. Monit. 2002, 8, RA268-RA273.
5. Schwarz, M. K.; Page, P. Preterm labour: An overview of current and emerging therapeutics. Curr. Med. Chem. 2003, 10, 1441-1468.
6. (a) Bossmar, T. Treatment of preterm labor with the oxytocin and vasopressin antagonist atosiban. J. Perinat. Med. 1998, 26, 458-465.
7. (b) Tsatsaris, V.; Carbonne, B.; Cabrol, D. Atosiban for preterm labour. Drugs 2004, 64, 375-382.
8. Williams, P. D.; Pettibone, D. J. Recent advances in the development of oxytocin receptor antagonists. Curr. Pharm. Des. 1996, 2, 41-58.
9. Freidinger, R. M.; Pettibone, D. J. Small molecule ligands for oxytocin and vasopressin receptors. Med. Res. Rev. 1997, 17, 1-16.
10. Vatish, M.; Thornton, S. Oxytocin antagonists. Expert Opin. Ther. Pat. 2002, 12, 1403-1406.
11. Wyatt, P. G.; Allen, M. J.; Borthwick, A. D.; Davies, D. E.; Exall, A. M.; Hatley, R. J. D.; Irving, W. R.; Livermore, D. G.; Miller, N. D.; Nerozzi, F.; Sollis, S. L.; Szardenings, A. K. 2,5-Diketopiperazines as potent and selective oxytocin antagonists. 1: Identification, stereochemistry and initial SAR. Bioorg. Med. Chem. Lett. 2005, 15, 2579-2582.
12. Josien, H.; Lavielle, S.; Brunissen, A.; Saffroy, M.; Torrens, Y.; Beaujouan, J.-C.; Glowinski, J.; Chassaing, G. Design and synthesis of side-chain conformationally restricted phenylalanines and their use for structure-activity studies on tachykinin NK-1 Receptor. J. Med. Chem. 1994, 37, 1586-1601.
13. Syldatk, C.; May, O.; Altenbuchner, J.; Mattes, R.; Siemann, M. Microbial hydantoinases. Industrial enzymes from the origin of life. Appl Microbiol Biotechnol 1999, 51, 293-309.
14. Ogawa, J.; Shimizu, S. Microbial enzymes: new industrial applications from traditional screening methods. Trends Biotechnol. 2001, 17, 13-20.
15. Sollis, S. L. A Novel stereospecific synthesis of 2,5-diketopipazines. J. Org. Chem. 2005, 70, 4735-4740.
16. Minimizations and energy calculations were carried out using MedChem Explorer (Accelerys) using a CFF force field.
17. d = 3.8 nM).
18. Wyatt, P. G.; Allen, M. J.; Chilcott, J.; Gardner, C. J.; Livermore, D. G.; Mordaunt, J. E.; Nerozzi, F.; Patel, M.; Perren, M. J.; Weingarten, G. G.; Shabbir, S.; Woollard, P. M.; Zhou, P. Identification of potent and selective oxytocin antagonists. Part 2: further investigation of benzofuran derivatives. Bioorg. Med. Chem. Lett. 2002, 12, 1405-1411.
19. Wood, S. P.; Tickle, I. J.; Treharne, A. M.; Pitts, J. E.; Mascarenhas, Y.; Li, J. Y.; Husain, J.; Cooper, S.; Blundell, T. L.; Hruby, V. J.; Buku, A.; Fischman, A. J.; Wyssbrod, H. R. Crystal structure analysis of deamino-oxytocin: conformational flexibility and receptor binding. Science 1986, 232 (4750), 633-636.
20. Zingg, H. H.; Laporte, S. A. The oxytocin receptor. Trends Endocrinol. Metab. 2003, 14, 222-227.
21. Havass, J.; Bakos, K.; Marki, A.; Gaspar, R.; Gera, L.; Stewart, J. M.; Fulop, F.; Toth, G. K.; Zupko, I.; Falkay, G. Noncompetitive nature of oxytocin antagonists with general structure Mpa1Xxx2Sar7Arg8. Peptides 2002, 23, 1419-1425.
22. Melin, P.; Trojnar, J.; Johansson, B.; Vilhardt, H.; Akerlund, M. Synthetic antagonists of the myometrial response to vasopressin and oxytocin. J Endocrinol. 1986, 111, 125-131.
23. Melin, P.; Vilhardt, H.; Lindeberg, G.; Larsson, L. E.; Akerlund, M. Inhibitory effect of O-alkylated analogues of oxytocin and vasopressin on human and rat myometrial activity. J. Endocrinol. 1981, 88, 173-180.
24. oct) from gradient RP-HPLC retention and a hydrogen bond acidity term (Σα2H). Curr. Med. Chem. 2001, 8, 1137-1146.
25. Valko, K. Separation Methods in Drug Synthesis and Purification. In Handbook of Analytical Separations; Valko, K., Ed.; Elsevier: Amsterdam, 2000; Vol. 1, Chapter 12, pp 535-583.
26. For HSA and RSA binding methods using Chromtech immobilized HSA and RSA HPLC columns, see the following. Valko, K.; Nunhuck, S.; Bevan, C.; Abraham, M. H.; Reynolds, D. P. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. J. Pharm Sci. 2003, 92, 2236-2248.
27. 3H] oxytocin was made up in buffer containing 100 mg/mL HSA. HSA was obtained from Sigma (Poole, Dorset, U.K.).
28. 50 is the serum concentration for 50% inhibition of uterine contractility response to oxytocin in an OT induced rat uterus contraction model (see ref 15).
29. -1 i.v.) 18 h after pretreatment with diethylstilbestrol (250 ug/kg ip). Arterial blood pressure was recorded from a femoral artery. The left uterine horn was anchored in the abdominal cavity at the ovarian end, and uterine contractility was recorded via a ligature tied approximately 2 cm distally and connected to a strain gauge under 1-2 g resting tension. Two consecutive two-point dose-response curves to either iv OT were constructed and uterine contractile responses quantified by recording the area under the contractile response for the 10 min period immediately postdose. Cumulative doses of antagonist or vehicle were then injected iv, and oxytocin dose-response curves were repeated 15 min later. Dose ratios were calculated for each dose of antagonist by comparison with the second agonist dose-response curve and the DR10 (antagonist dose required to shift the agonist dose-response curve 10-fold), calculated by linear interpolation of log-(DR-1) plotted against dose (mg/kg).
30. Bowers, N. I.; Boyd, D. R.; Sharma, N. D.; Goodrich, P. A.; Groocock, M. R.; Blacker, A. J.; Goode, P.; Dalton, H. Stereoselective benzylic hydroxylation of 2-substituted indanes using toluene dioxygenase as biocatalyst. J. Chem. Soc., Perkin Trans. 1 1999, 11, 1453-1462.
31. Quan, M. L.; Lam, P. Y. S.; Han, Q.; Pinto, D. J. P.; He, M. Y.; Li, R.; Ellis, C. D.; Clark, C. G.; Teleha, C. A.; Sun, J.-H.; Alexander, R. S.; Bai, S.; Luettgen, J. M.; Knabb, R. M.; Wong, P. C.; Wexler, R. R. Discovery of 1-(3′-Aminobenzisoxazol-5′-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2′-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (Razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor J. Med. Chem. 2005, 48, 1729-1744.